According to filings with the U.S. Securities and Exchange Commission, Rapalogix Health has raised $20,000,000.00 in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Norwest, Base10 Partners, Twilio Ventures, and Y Combinator

About Rapalogix Health
Rapalogix Health is a California-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products. Re-Q Pro-Longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at dermatology and aesthetic practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.

To learn more, visit https://www.rapalogix.com/
Linkedin: https://www.linkedin.com/company/rapalogix/

Contact:
Rahul Mehta, Chief Executive Officer
https://www.linkedin.com/in/rahulmehtaphd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.